Allogene Therapeutics Inc.
ALLO | NASDAQ
$1.71
+$0.02 (+1.18%)
At close: Sep 22, 2026, 4:00 PM ET
$1.74
+$0.03 (+1.71%)
After-hours:
Sep 22, 2026, 7:54 PM ET
Market Data
Market Cap $583.31M
Enterprise Value $321.06M
Beta 0.48
Average Volume 7.22M
Shares Outstanding (Diluted) 328.93M
Shares Change YoY 50.24%
Institutional Ownership 76.65%
Exchange NASDAQ
ISIN US0197701065
Price Performance
Price Change 1M -19.9%
Price Change 3M -18.4%
Price Change 6M -27.5%
Price Change YTD 25.2%
Price Change 1Y 44.4%
Price Change 3Y -53.7%
Price Change 5Y -93.4%
1M CAGR (ann.) -15.9%
1Y CAGR (ann.) 39.7%
5Y CAGR (ann.) -41.5%
All-Time CAGR -28.7%
Valuation
PE Ratio -2.52
Forward PE N/A
PEG Ratio -0.04
Forward PEG -0.44
PS Ratio 125.71
Forward PS 43.40
PB Ratio 1.34
P/FCF Ratio -5.69
P/Adj. FCF Ratio -4.16
P/OCF Ratio -5.45
EV/Sales 69.19
EV/EBIT -1.96
EV/EBITDA -2.10
EV/FCF -3.13
Earnings Yield -39.6%
FCF Yield -17.6%
Adj. FCF Yield -24.0%
Financial Health
Net Cash $332.6M
Total Debt $70.35M
Cash & Short-Term Investments $332.6M
Total Assets $550.09M
Current Ratio 10.72
Quick Ratio 10.72
Debt / Equity Ratio 0.16
Debt / EBITDA -0.46
Debt / FCF -0.69
OCF / Debt -1.45
Interest Coverage -138.71
Altman Z-Score -2.57
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin -699.4%
Operating Profit Margin -3886.1%
EBITDA Margin -3287.2%
Net Profit Margin -3566.7%
FCF Margin -2211.2%
Adj. FCF Margin -3019.2%
SBC / Revenue 808.0%
SBC Impact (per share) -36.5%
Returns
Return on Assets -30.1%
Return on Equity -50.0%
Return on Invested Capital -34.8%
Return on Capital Employed -34.8%
Return on Tangible Assets -30.1%
Historical Growth (CAGR)
Revenue CAGR 3Y 215.3%
Revenue CAGR 5Y -34.5%
Revenue CAGR 10Y N/A
EPS CAGR 3Y 41.6%
EPS CAGR 5Y 27.3%
EPS CAGR 10Y N/A
FCF CAGR 3Y 37.5%
FCF CAGR 5Y 15.0%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 30
EPS Growth Next 3Y N/A
Revenue Growth Next 3Y 323.0%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$0.13
EPS Growth Est (next Q) -31.6%
Revenue Est (next Q) $2.5K
Revenue Growth Est (next Q) N/A
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $6.43
Price Target Upside 280.5%
Cash Flow
Operating Cash Flow $-102.2M
Free Cash Flow $-102.6M
Adj. Free Cash Flow $-140.09M
FCF Per Share -$0.31
OCF Per Share -$0.31
OCF/S Ratio -2202.5%
Income Statement
Revenue $4.64M
Gross Profit $-32.45M
Operating Income $-180.32M
EBITDA $-152.53M
Net Income $-165.49M
EPS (Diluted) -$0.67
Revenue / Employee $30.73K
Profit / Employee $-1.1M
Employees 151
Add to Watchlist
Select watchlists to add or remove ALLO